According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

both of which are positioned for indication expansions into severe asthma and COPD. The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors ...

Sales were also boosted by demand for the anti-inflammatory drug Dupixent, a treatment for eczema, asthma and, more recently, chronic obstructive pulmonary disease, among other indications.

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Apart from Eylea, profits from asthma drug Dupixent’s sales are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara.